17β‐Estradiol Matrixpatch Removal and Reapplication in Postmenopausal Women: Experimental Results

Comparison of steady state development and reduction of menopausal symptoms after oral or transdermal delivery of 17-β-estradiol in young healthy symptomatic menopausal women

“…We found excellent agreement between experimentally determined E2 plasma values compared to those theoretically predicted [4,5]. We assumed linear E2 pharmacokinetics as supported in the literature [4,5].…”

“…We did report in the literature multiple consecutively dosing of a transdermal delivery of estradiol (E2) by a matrix patch in early symptomatic menopausal women and compared plasma profiles with those theoretically predicted [4,5]. We found excellent agreement between experimentally determined E2 plasma values compared to those theoretically predicted [4,5].…”

“…As there is a newly sparked interest in E2 delivery, several questions still remain concerning E2 steady state delivery, the relationship between pharmacokinetics and dynamics, as well as a comparison between oral and transdermal pharmacokinetics and pharmacodynamics. Previously we published the pharmacokinetic of transdermal delivery with a matrix patch [4,5]. We reported a surprise finding that the transdermal delivery of E2 by a matrix patch steady state condition is achieved within the first matrix patch application, which was later corroborated for a contraceptive patch containing E2 that utilized the same matrix technology [6].…”

“…The pharmacokinetic analysis is difficult because circadian E2 plasma rhythms exist in premenopausal women and the transdermal and ovarian uptake may be partially influenced by blood perfusion [4,5]. It is therefore of interest whether circadian plasma values exist for oral delivery too.…”

“…We therefore decided to investigate the steady state condition for immediate oral delivery. In contrast to our previous steady state investigation with a matrix patch for Table 1 Key characteristics of participating menopausal women [3,4,12].…”